Orchestra BioMed Receives $6.1M Milestone Payment from Haemonetics

Key Facts

1Orchestra BioMed received a $6.1 million milestone payment following Haemonetics Corporation's acquisition of Vivasure Medical.

2This payment brings the total cash proceeds received by the company from this strategic holding to approximately $11 million.

3The company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts.

In a move that highlights the strategic monetization of biotech holdings, Orchestra BioMed announced the receipt of a $6.1 million milestone payment triggered by Haemonetics Corporation's acquisition of Vivasure Medical. According to reports, this payment increases the total cash proceeds received by the company from this strategic investment to approximately $11 million. Furthermore, the company remains eligible for up to $10 million in additional proceeds through future revenue earnouts based on specific performance targets.

These cash inflows come as medical technology firms focus on extracting value from strategic partnerships and holdings. Per market data, Haemonetics (HAE) closed at $106.31, while Orchestra BioMed (OBIO) stood at $5.9 as of the September 14, 2026 close. This latest payment completes a significant portion of the total potential proceeds from the transaction, which could eventually reach $21 million.

Monitoring current price levels, OBIO shares reached a high of $6.2 and a low of $5.74 at the close on September 14, 2026. Investors will be watching how the company utilizes this capital to fund its pivotal clinical programs. There are no major upcoming sector-specific catalysts noted in the economic calendar for the immediate week ahead.